NCT00664599View on ClinicalTrials.gov

Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Behcet's Syndrome
Interventions
DRUG

Rituximab

Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).

DRUG

Cytotoxic Combination

Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.

Trial Locations (1)

14114

Rheumatology Research Center, Shariati Hospital, Tehran

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Tehran University of Medical Sciences

OTHER

NCT00664599 - Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease | Biotech Hunter | Biotech Hunter